宣肺平喘方治疗小儿哮喘的疗效观察及其对呼出气一氧化氮的影响
作者: |
1陈文婷,
2苏克雷
1 溧阳市中医医院儿科,江苏 常州 213300 2 江苏省中医药研究院,南京 210028 |
通讯: |
陈文婷
Email: cwtlyp@163.com |
DOI: | 10.3978/j.issn.2095-6959.2019.08.008 |
基金: | 国家自然科学青年基金(81503573)。 |
摘要
目的:评价宣肺平喘方治疗小儿哮喘的临床疗效及其对呼出气一氧化氮(FeNO)的影响。方法:将80例支气管哮喘患儿按随机数字表法分为对照组与研究组,每组各40例。对照组予西医规范治疗,研究组在西医规范治疗的基础上,加予口服宣肺平喘方,连续治疗2周后,比较患者在临床疗效、中医症候积分、炎症指标[白细胞计数(white blood cell count,WBC)、高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、白介素-6(IL-6)]、肺功能[1秒用力呼气容积(FEV1)、1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)]及FeNO的差异。结果:经治疗,对照组总有效率82.5%,研究组为92.5%,研究组临床疗效优于对照组,差异有统计学意义(P<0.05)。治疗前,两组在气喘、胸闷、咳嗽、咳痰等症状上,差异无统计学意义(P>0.05);治疗后,研究组在症状改善上优于对照组,差异有统计学意义(P<0.05)。与治疗前相比,对照组治疗后除胸闷症状外,其余症状均显著改善,差异有统计学意义(P<0.05);研究组在各症状均显著改善,差异有统计学意义(P<0.05)。治疗前,两组在WBC,hs-CRP,IL-6,FEV1,FEV1/FVC及FeNO等指标上,差异无统计学意义(P>0.05);治疗后,2组各指标相比,差异有统计学意义(P<0.05或P<0.01)。两组经治疗,各项指标均显著改善,差异有统计学意义(P<0.05或P<0.01)。结论:宣肺平喘方治疗小儿哮喘疗效确切,能显著改善患儿症状,降低炎症指标,改善肺功能,且无明显不良反应,联合西药治疗效果更佳。
关键词:
宣肺平喘方;小儿哮喘;临床疗效;呼出气一氧化氮
Therapeutic effect of Xuanfei Pingchuan Recipe on children with asthma and its effect on FeNO
CorrespondingAuthor: CHEN Wenting Email: cwtlyp@163.com
DOI: 10.3978/j.issn.2095-6959.2019.08.008
Foundation: This work was supported by the National Science Foundation for Young Scientists, China (81503573).
Abstract
Objective: To evaluate the clinical efficacy of Xuanfei Pingchuan Recipe in treating children with asthma and its effect on exhaled nitric oxide (FeNO). Methods: Eighty children with bronchial asthma were divided into a control group and a study group according to the random number table method, 40 cases in each group. The control group was treated with Western medicine. The research group was treated with oral Xuanfei Pingchuan Recipe on the basis of Western medicine standard treatment. After 2 weeks of continuous treatment, the patients were compared in clinical efficacy, TCM symptom scores, inflammation index (WBC, hs-CRP, IL-6), lung function (FEV1, FEV1/FVC) and FeNO. Results: After the treatment, the total effective rate of the control group was 82.5%, and that of the study group was 92.5%. The clinical effect of the study group was better than that of the control group, and the difference was statistically significant (P<0.05). Before the treatment, the differences between the two groups in asthma, chest tightness, cough, cough and other symptoms were not statistically significant (P>0.05). After the treatment, the study group was better than the control group in terms of symptom improvement. The difference was statistically significant (P<0.05). After the treatment, the control groups were significantly improved except for the symptoms of chest tightness, and the difference was statistically significant (P<0.05). The study group showed significant improvement in each symptom, and the difference was statistically significant (P<0.05, P<0.01). Before the treatment, there were no significant differences in WBC, hs-CRP and IL-6 between the two groups (P>0.05). After the treatment, the inflammatory indexes of the study group were significantly lower than the control group, and the difference was statistically significant (P<0.05). After the treatment, the inflammatory indexes of the two groups were significantly decreased, and the difference was statistically significant (P<0.05, P<0.01). Before the treatment, there was no significant difference in the indexes of FEV1, FEV1/FVC and FeNO between the two groups (P>0.05). After the treatment, the indexes of the study group were significantly better than the control group, and the difference was statistically significant (P<0.01). After the treatment, the indexes of the two groups were significantly improved, and the difference was statistically significant (P<0.01). Conclusion: Xuanfei Pingchuan Recipe is effective in the treatment of children with asthma, can significantly improve the symptoms of children, reduce inflammation indicators, improve lung function, and have no obvious adverse reactions. The clinical efficacy is better when combined with western medicine treatment.
Keywords:
Xuanfei Pingchuan Recipe; pediatric asthma; clinical efficacy; FeNO